SUTRO BIOPHARMA, INC. Revenue Breakdown
No Revenue Breakdown for STRO on this site yet.
- 2025-12-31: Others Not split by product in the filing$102.48M100.00%; Total revenue $102.48M.
- 2024-12-31: Others Not split by product in the filing$62.04M100.00%; Total revenue $62.04M.
- 2023-12-31: Others Not split by product in the filing$153.73M100.00%; Total revenue $153.73M.
- 2022-12-31: Others Not split by product in the filing$67.77M100.00%; Total revenue $67.77M.
Source checked: the stored Revenue Breakdown page for STRO.
Revenue by product
Each year (12 month)
| Fiscal year end | Others | Total revenue |
|---|---|---|
| 2025-12-31 | Not split by product in the filing $102.48M 100.00% | $102.48M |
| 2024-12-31 | Not split by product in the filing $62.04M 100.00% | $62.04M |
| 2023-12-31 | Not split by product in the filing $153.73M 100.00% | $153.73M |
| 2022-12-31 | Not split by product in the filing $67.77M 100.00% | $67.77M |
| 2021-12-31 | Not split by product in the filing $61.88M 100.00% | $61.88M |
| 2020-12-31 | Not split by product in the filing $42.72M 100.00% | $42.72M |
| 2019-12-31 | Not split by product in the filing $42.74M 100.00% | $42.74M |
| 2018-12-31 | Not split by product in the filing $38.42M 100.00% | $38.42M |
| 2017-12-31 | Not split by product in the filing $51.74M 100.00% | $51.74M |
| 2016-12-31 | Not split by product in the filing $59.73M 100.00% | $59.73M |
Each quarter (3 month)
| Quarter end | Others | Total revenue |
|---|---|---|
| 2026-06-30 | Not split by product $9.84M 100.00% | $9.84M |
| 2026-03-31 | Not split by product $14.52M 100.00% | $14.52M |
| 2025-12-31 | Not split by product $11.65M 100.00% | $11.65M |
| 2025-09-30 | Not split by product $9.69M 100.00% | $9.69M |
| 2025-06-30 | Not split by product $63.74M 100.00% | $63.74M |
| 2025-03-31 | Not split by product $17.40M 100.00% | $17.40M |
| 2024-12-31 | Not split by product $14.81M 100.00% | $14.81M |
| 2024-09-30 | Not split by product $8.52M 100.00% | $8.52M |
| 2024-06-30 | Not split by product $25.71M 100.00% | $25.71M |
| 2024-03-31 | Not split by product $13.01M 100.00% | $13.01M |
| 2023-12-31 | Not split by product $113.72M 100.00% | $113.72M |
| 2023-09-30 | Not split by product $16.92M 100.00% | $16.92M |
| 2023-06-30 | Not split by product $10.41M 100.00% | $10.41M |
| 2023-03-31 | Not split by product $12.67M 100.00% | $12.67M |
| 2022-12-31 | Not split by product $8.63M 100.00% | $8.63M |
| 2022-09-30 | Not split by product $25.15M 100.00% | $25.15M |
| 2022-06-30 | Not split by product $28.10M 100.00% | $28.10M |
| 2022-03-31 | Not split by product $5.90M 100.00% | $5.90M |
| 2021-12-31 | Not split by product $10.65M 100.00% | $10.65M |
| 2021-09-30 | Not split by product $8.52M 100.00% | $8.52M |
| 2021-06-30 | Not split by product $28.05M 100.00% | $28.05M |
| 2021-03-31 | Not split by product $14.66M 100.00% | $14.66M |
| 2020-12-31 | Not split by product $8.28M 100.00% | $8.28M |
| 2020-09-30 | Not split by product $17.82M 100.00% | $17.82M |
| 2020-06-30 | Not split by product $9.47M 100.00% | $9.47M |
| 2020-03-31 | Not split by product $7.15M 100.00% | $7.15M |
| 2019-12-31 | Not split by product $11.30M 100.00% | $11.30M |
| 2019-09-30 | Not split by product $12.28M 100.00% | $12.28M |
| 2019-06-30 | Not split by product $10.53M 100.00% | $10.53M |
| 2019-03-31 | Not split by product $8.63M 100.00% | $8.63M |
| 2018-12-31 | Not split by product $19.09M 100.00% | $19.09M |
| 2018-09-30 | Not split by product $7.84M 100.00% | $7.84M |
| 2018-06-30 | Not split by product $5.70M 100.00% | $5.70M |
| 2018-03-31 | Not split by product $5.79M 100.00% | $5.79M |
| 2017-12-31 | Not split by product $4.04M 100.00% | $4.04M |
| 2017-09-30 | Not split by product $17.50M 100.00% | $17.50M |
| 2017-06-30 | Not split by product $15.36M 100.00% | $15.36M |
| 2017-03-31 | Not split by product $14.85M 100.00% | $14.85M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |